HK1185763A1 - 丙型肝炎病毒抑制劑 - Google Patents
丙型肝炎病毒抑制劑Info
- Publication number
- HK1185763A1 HK1185763A1 HK13113396.8A HK13113396A HK1185763A1 HK 1185763 A1 HK1185763 A1 HK 1185763A1 HK 13113396 A HK13113396 A HK 13113396A HK 1185763 A1 HK1185763 A1 HK 1185763A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- hepatitis
- virus
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40697210P | 2010-10-26 | 2010-10-26 | |
US201161438429P | 2011-02-01 | 2011-02-01 | |
US201161524220P | 2011-08-16 | 2011-08-16 | |
PCT/US2011/057398 WO2012058125A1 (en) | 2010-10-26 | 2011-10-21 | Inhibitors of hepatitis c virus |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1185763A1 true HK1185763A1 (zh) | 2014-02-28 |
Family
ID=45994336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK13113396.8A HK1185763A1 (zh) | 2010-10-26 | 2013-12-02 | 丙型肝炎病毒抑制劑 |
Country Status (21)
Country | Link |
---|---|
US (4) | US20130302282A1 (zh) |
EP (1) | EP2632261B1 (zh) |
JP (1) | JP5731004B2 (zh) |
KR (1) | KR101594166B1 (zh) |
CN (1) | CN103269586B (zh) |
AR (1) | AR083565A1 (zh) |
AU (1) | AU2011320696B2 (zh) |
BR (1) | BR112013009789A2 (zh) |
CA (1) | CA2815537A1 (zh) |
CL (1) | CL2013001141A1 (zh) |
CO (1) | CO6700883A2 (zh) |
EA (1) | EA025151B1 (zh) |
HK (1) | HK1185763A1 (zh) |
IL (1) | IL225853A0 (zh) |
MX (1) | MX2013004655A (zh) |
NZ (1) | NZ609564A (zh) |
PE (1) | PE20140109A1 (zh) |
SG (1) | SG189985A1 (zh) |
TW (1) | TWI486348B (zh) |
WO (1) | WO2012058125A1 (zh) |
ZA (1) | ZA201303752B (zh) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8354419B2 (en) | 2009-07-16 | 2013-01-15 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of flavivirus infections |
JP5833022B2 (ja) * | 2010-01-27 | 2015-12-16 | エービー・ファーマ・リミテッド | C型肝炎ウィルス阻害剤としてのポリ複素環式化合物 |
WO2011119853A1 (en) | 2010-03-24 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
CN103269586B (zh) | 2010-10-26 | 2015-07-15 | 普雷西迪奥制药公司 | 丙型肝炎病毒抑制剂 |
GB2515942A (en) * | 2011-10-21 | 2015-01-07 | Abbvie Inc | Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV |
WO2013163466A1 (en) * | 2012-04-25 | 2013-10-31 | Presidio Pharmaceuticals, Inc. | Inhibitors of hepatitis c virus |
JP2016505011A (ja) | 2013-01-10 | 2016-02-18 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C型肝炎の治療用の大環状ベンゾフランおよびアザベンゾフラン化合物 |
WO2015143257A1 (en) | 2014-03-21 | 2015-09-24 | Bristol-Myers Squibb Company | 6h-furo[2,3-e]indole compounds for the treatment of hepatitis c |
US9920036B2 (en) * | 2014-03-21 | 2018-03-20 | Bristol-Myers Squibb Company | Cyanoamino (aza)benzofuran compounds for the treatment of hepatitis C |
SG11201607750PA (en) | 2014-03-21 | 2016-10-28 | Bristol Myers Squibb Co | Cyano containing azabenzofuran compounds for the treatment of hepatitis c |
US9840511B2 (en) | 2014-05-21 | 2017-12-12 | Bristol-Meyers Squibb Company | 2-(aryl or heteroaryl-)phenyl (AZA)benzofuran compounds for the treatment of hepatitis C |
EP3154963A1 (en) | 2014-06-11 | 2017-04-19 | Bristol-Myers Squibb Company | Substituted 2-phenyl (aza)benzofuran compounds for the treatment of hepatitis c |
US9957278B2 (en) | 2014-08-05 | 2018-05-01 | Bristol-Myers Squibb Company | Furopyridine compounds for the treatment of hepatitis C |
US10202403B2 (en) | 2014-10-02 | 2019-02-12 | Bristol-Myers Squibb Company | Macrocyclic benzofuran compounds for the treatment of hepatitis C |
US10087167B2 (en) | 2015-02-19 | 2018-10-02 | Bristol-Myers Squibb Company | Benzofurans substituted with secondary benzamide as HCV inhibitors |
US10125111B2 (en) | 2015-02-19 | 2018-11-13 | Bristol-Myers Squibb Company | Benzofuran compounds for the treatment of hepatitis C |
US10131645B2 (en) | 2015-02-19 | 2018-11-20 | Bristol-Myers Squibb Company | Benzofurans substituted with primary benzamide as HCV inhibitors |
WO2016133972A1 (en) | 2015-02-19 | 2016-08-25 | Bristol-Myers Squibb Company | Substituted benzofuran compounds for the treatment of hepatitis c |
WO2016133961A1 (en) | 2015-02-19 | 2016-08-25 | Bristol-Myers Squibb Company | Benzofurans substituted with bicyclic secondary benzamide as hcv inhibitors |
US11831699B2 (en) * | 2016-09-08 | 2023-11-28 | Harmonic, Inc. | Using web-based protocols to assist graphic presentations when providing digital video |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7741A (en) | 1850-10-29 | Cak-cottpling | ||
US347A (en) | 1837-08-08 | dixon | ||
US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
JP4094066B2 (ja) | 1996-12-06 | 2008-06-04 | バーテックス ファーマシューティカルズ インコーポレイテッド | インターロイキン−1β変換酵素のインヒビター |
EE200100492A (et) | 1999-03-19 | 2002-12-16 | Vertex Pharmaceuticals Incorporated | Ensüümi IMPDH inhibiitorid |
US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
EP1256628A3 (en) | 2001-05-10 | 2003-03-19 | Agouron Pharmaceuticals, Inc. | Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof |
WO2002100846A1 (en) | 2001-06-11 | 2002-12-19 | Shire Biochem Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
PL208713B1 (pl) | 2001-06-11 | 2011-05-31 | Virochem Pharma Inc | Związek stanowiący pochodną tiofenu, kompozycja farmaceutyczna zawierająca taki związek i jego zastosowanie |
AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
US6841566B2 (en) | 2001-07-20 | 2005-01-11 | Boehringer Ingelheim, Ltd. | Viral polymerase inhibitors |
EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
WO2003037895A1 (en) | 2001-11-02 | 2003-05-08 | Glaxo Group Limited | 4-(6-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors |
CA2504344A1 (en) | 2002-11-01 | 2004-05-21 | Viropharma Incorporated | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases |
MXPA05012101A (es) * | 2003-05-09 | 2006-02-08 | Boehringer Ingelheim Int | Bolsillo de union al inhibidor de polimerasa ns5b del virus de la hepatitis c. |
AR048401A1 (es) | 2004-01-30 | 2006-04-26 | Medivir Ab | Inhibidores de la serina-proteasa ns3 del vhc |
EP1746888A2 (en) | 2004-05-13 | 2007-01-31 | Viropharma Incorporated | Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
WO2006019831A1 (en) | 2004-07-14 | 2006-02-23 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
JP5015154B2 (ja) * | 2005-08-12 | 2012-08-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ウイルスポリメラーゼインヒビター |
WO2007059421A2 (en) | 2005-11-10 | 2007-05-24 | Wyeth | Polymorphs of 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl) amino]-n-methyl-1-benzofuran-3-carboxamide and methods of making the same |
WO2007138242A1 (en) | 2006-05-30 | 2007-12-06 | Arrow Therapeutics Limited | Biphenyl derivatives and their use in treating hepatitis c |
GB0614940D0 (en) | 2006-07-27 | 2006-09-06 | Arternis Intelligent Power Ltd | Vehicle traction and stability control system employing control of fluid quanta |
US8303944B2 (en) | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7759495B2 (en) | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7659270B2 (en) | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2008082725A1 (en) | 2006-12-29 | 2008-07-10 | Anadys Pharmaceuticals, Inc. | Pyridazinone compounds |
US20090047246A1 (en) | 2007-02-12 | 2009-02-19 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
GB0707000D0 (en) * | 2007-04-12 | 2007-05-30 | Istituto Di Ricerche D Biolog | Antiviral agents |
CN105567672A (zh) | 2007-05-23 | 2016-05-11 | Vgxi公司 | 包含高浓度的生物活性分子的组合物及其制备工艺 |
US7728027B2 (en) | 2007-08-08 | 2010-06-01 | Bristol-Myers Squibb Company | Process for synthesizing compounds useful for treating hepatitis C |
JP2010535773A (ja) | 2007-08-10 | 2010-11-25 | グラクソスミスクライン エルエルシー | ウイルス感染を治療するための窒素含有二環式化学物質 |
CN101821252A (zh) | 2007-08-29 | 2010-09-01 | 先灵公司 | 取代的吲哚衍生物及其使用方法 |
KR100903412B1 (ko) | 2007-10-16 | 2009-06-18 | (주)다산알앤디 | 자동속도조절 러닝머신, 그 제어모듈 및 그 제어방법 |
CA2705587A1 (en) | 2007-11-16 | 2009-05-22 | Schering Corporation | 3-aminosulfonyl substituted indole derivatives and methods of use thereof |
US7704992B2 (en) | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8147818B2 (en) | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
AU2009214194B2 (en) | 2008-02-14 | 2012-05-17 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
WO2009137493A1 (en) | 2008-05-05 | 2009-11-12 | Wyeth | 2-substituted benzofuran compounds to treat infection with hepatitis c virus |
WO2009137500A1 (en) * | 2008-05-05 | 2009-11-12 | Wyeth | 6-substituted benzofuran compounds to treat infection with hepatitis c virus |
CN101635673B (zh) | 2008-07-25 | 2012-01-25 | 华为技术有限公司 | 预订路径的方法、***及路径计算客户、路径计算单元 |
US7906655B2 (en) | 2008-08-07 | 2011-03-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8198449B2 (en) | 2008-09-11 | 2012-06-12 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US8293909B2 (en) | 2008-09-11 | 2012-10-23 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US8048887B2 (en) | 2008-09-11 | 2011-11-01 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7994171B2 (en) | 2008-09-11 | 2011-08-09 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
JP2010092550A (ja) | 2008-10-09 | 2010-04-22 | Hitachi Global Storage Technologies Netherlands Bv | 磁気記録ヘッド、その製造方法及び磁気記録再生装置 |
WO2010062821A1 (en) | 2008-11-28 | 2010-06-03 | Glaxosmithkline Llc | Anti-viral compounds, compositions, and methods of use |
US8865756B2 (en) | 2008-12-03 | 2014-10-21 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
JP2012513410A (ja) | 2008-12-23 | 2012-06-14 | アボット・ラボラトリーズ | 抗ウイルス化合物 |
WO2010096462A1 (en) | 2009-02-17 | 2010-08-26 | Enanta Pharmaceuticals, Inc | Linked diimidazole derivatives |
TWI438200B (zh) | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | C型肝炎病毒抑制劑 |
WO2010094977A1 (en) | 2009-02-23 | 2010-08-26 | Arrow Therapeutics Limited | Novel biphenyl compounds useful for the treatment of hepatitis c |
KR20110136819A (ko) * | 2009-02-27 | 2011-12-21 | 시가 테크놀로지스, 인크. | 뎅기 바이러스 감염의 치료 및 예방을 위한 티에노피리딘 유도체 |
BRPI1010900A2 (pt) | 2009-05-20 | 2016-03-15 | Hoffmann La Roche | compostos antivirais heterocíclicos |
US20130156731A1 (en) * | 2009-12-22 | 2013-06-20 | Kevin X. Chen | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas |
TW201138786A (en) | 2010-02-19 | 2011-11-16 | Glaxo Group Ltd | Therapeutic compounds |
WO2011106929A1 (en) | 2010-03-02 | 2011-09-09 | Merck Sharp & Dohme Corp. | Inhibitors of hepatitis c virus ns5b polymerase |
WO2011106986A1 (en) | 2010-03-02 | 2011-09-09 | Merck Sharp & Dohme Corp. | Inhibitors of hepatitis c virus ns5b polymerase |
AR080433A1 (es) | 2010-03-02 | 2012-04-11 | Merck Sharp & Dohme | Derivados de benzofurancarboxamidas utiles para tratar o prevenir infecciones por vhc y composiciones farmaceuticas que los contienen. |
PE20130062A1 (es) * | 2010-03-09 | 2013-02-28 | Merck Sharp & Dohme | Compuestos de sililo triciclicos fusionados para el tratamiento de enfermedades virales |
WO2011112186A1 (en) | 2010-03-10 | 2011-09-15 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis c |
US8354410B2 (en) | 2010-03-11 | 2013-01-15 | Bristol-Meyers Squibb Company | Compounds for the treatment of hepatitis C |
WO2011112191A1 (en) | 2010-03-11 | 2011-09-15 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis c |
AR082453A1 (es) * | 2010-04-21 | 2012-12-12 | Novartis Ag | Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos |
CN103269586B (zh) | 2010-10-26 | 2015-07-15 | 普雷西迪奥制药公司 | 丙型肝炎病毒抑制剂 |
WO2013163466A1 (en) * | 2012-04-25 | 2013-10-31 | Presidio Pharmaceuticals, Inc. | Inhibitors of hepatitis c virus |
-
2011
- 2011-10-21 CN CN201180061899.2A patent/CN103269586B/zh not_active Expired - Fee Related
- 2011-10-21 WO PCT/US2011/057398 patent/WO2012058125A1/en active Application Filing
- 2011-10-21 BR BR112013009789A patent/BR112013009789A2/pt not_active IP Right Cessation
- 2011-10-21 JP JP2013536688A patent/JP5731004B2/ja not_active Expired - Fee Related
- 2011-10-21 KR KR1020137013396A patent/KR101594166B1/ko not_active IP Right Cessation
- 2011-10-21 NZ NZ609564A patent/NZ609564A/en not_active IP Right Cessation
- 2011-10-21 EP EP11836903.2A patent/EP2632261B1/en not_active Not-in-force
- 2011-10-21 AU AU2011320696A patent/AU2011320696B2/en not_active Expired - Fee Related
- 2011-10-21 CA CA2815537A patent/CA2815537A1/en not_active Abandoned
- 2011-10-21 US US13/882,138 patent/US20130302282A1/en not_active Abandoned
- 2011-10-21 MX MX2013004655A patent/MX2013004655A/es active IP Right Grant
- 2011-10-21 EA EA201390433A patent/EA025151B1/ru not_active IP Right Cessation
- 2011-10-21 PE PE2013000909A patent/PE20140109A1/es not_active Application Discontinuation
- 2011-10-21 SG SG2013031141A patent/SG189985A1/en unknown
- 2011-10-26 TW TW100138978A patent/TWI486348B/zh not_active IP Right Cessation
- 2011-10-26 AR ARP110103963A patent/AR083565A1/es unknown
-
2012
- 2012-04-25 US US13/456,181 patent/US9085587B2/en not_active Expired - Fee Related
- 2012-07-09 US US13/544,261 patent/US8614207B2/en not_active Expired - Fee Related
-
2013
- 2013-04-21 IL IL225853A patent/IL225853A0/en unknown
- 2013-04-25 CL CL2013001141A patent/CL2013001141A1/es unknown
- 2013-05-23 ZA ZA2013/03752A patent/ZA201303752B/en unknown
- 2013-05-24 CO CO13128218A patent/CO6700883A2/es active IP Right Grant
- 2013-11-18 US US14/083,429 patent/US9309260B2/en not_active Expired - Fee Related
- 2013-12-02 HK HK13113396.8A patent/HK1185763A1/zh not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL269662A (en) | Hepatitis C virus inhibitors | |
IL224369B (en) | Combinations of inhibitors for hepatitis c virus | |
HK1185763A1 (zh) | 丙型肝炎病毒抑制劑 | |
IL221033A0 (en) | Hepatitis c virus inhibitors | |
EP2575819A4 (en) | INHIBITORS OF HEPATITIS C VIRUS | |
IL224298A (en) | Hepatitis virus inhibitors c | |
EP2603080A4 (en) | HEPATITIS C-VIRUS HEMMER | |
ZA201306720B (en) | Hepatitis c virus inhibitors | |
AP2012006413A0 (en) | Inhibitors of flaviviridae viruses | |
AP2012006414A0 (en) | Inhibitors of flaviviridae viruses | |
IL229270A0 (en) | Hepatitis c virus inhibitors | |
EP2768517A4 (en) | HEPATITIS C-VIRUS HEMMER | |
ZA201309356B (en) | Hepatitis c virus inhibitors | |
EP2651906A4 (en) | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20191017 |